ATE375160T1 - Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen - Google Patents

Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen

Info

Publication number
ATE375160T1
ATE375160T1 AT00957914T AT00957914T ATE375160T1 AT E375160 T1 ATE375160 T1 AT E375160T1 AT 00957914 T AT00957914 T AT 00957914T AT 00957914 T AT00957914 T AT 00957914T AT E375160 T1 ATE375160 T1 AT E375160T1
Authority
AT
Austria
Prior art keywords
benicaent
mesoprogestins
hormone
prevention
dependent
Prior art date
Application number
AT00957914T
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE375160T1 publication Critical patent/ATE375160T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT00957914T 1999-08-31 2000-08-31 Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen ATE375160T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
ATE375160T1 true ATE375160T1 (de) 2007-10-15

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957914T ATE375160T1 (de) 1999-08-31 2000-08-31 Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen

Country Status (34)

Country Link
EP (1) EP1229906B1 (de)
JP (1) JP2003535029A (de)
KR (3) KR100864547B1 (de)
AR (1) AR025457A1 (de)
AT (1) ATE375160T1 (de)
AU (1) AU781840B2 (de)
BG (1) BG65817B1 (de)
BR (1) BR0014161A (de)
CA (1) CA2382580C (de)
CO (1) CO5200772A1 (de)
CZ (1) CZ2002704A3 (de)
DE (1) DE60036723T2 (de)
DK (1) DK1229906T3 (de)
EA (1) EA007854B1 (de)
EE (1) EE05172B1 (de)
ES (1) ES2295050T3 (de)
HR (1) HRP20020267A2 (de)
HU (1) HUP0202429A3 (de)
IL (1) IL148416A0 (de)
LT (1) LT5034B (de)
LV (1) LV12941B (de)
ME (1) MEP13808A (de)
MX (1) MXPA02002191A (de)
NO (1) NO20020999L (de)
NZ (1) NZ517471A (de)
PE (1) PE20010578A1 (de)
PL (1) PL198790B1 (de)
PT (1) PT1229906E (de)
RO (1) RO122179B1 (de)
RS (1) RS50283B (de)
SI (1) SI20852B (de)
SK (1) SK287192B6 (de)
UA (1) UA78184C2 (de)
WO (1) WO2001015679A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1525215B1 (de) * 2002-08-02 2006-09-06 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
ES2474765T3 (es) * 2009-06-17 2014-07-09 National University Corporation Kumamoto University Agente profiláctico y/o terapéutico para la dismenorrea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
PT800519E (pt) * 1994-12-22 2004-03-31 Ligand Pharm Inc Compostos moduladores de receptores de esteroides e metodos
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
AU714959B2 (en) 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
DK0900234T3 (da) * 1996-05-01 2000-11-06 Us Gov Health & Human Serv 21-substituerede progesteronderivater anvendt som nye antigestagener
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (de) * 1999-01-14 2001-10-17 Bayer Corporation Substituierte 2-arylamino-heterocyclen und diese enthaltende zusammensetzungen zur verwendung als mittel, die den progesteron-rezeptor binden
CA2371273A1 (en) * 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
CA2382580A1 (en) 2001-03-08
MXPA02002191A (es) 2002-09-30
KR20080066095A (ko) 2008-07-15
EA007854B1 (ru) 2007-02-27
WO2001015679A3 (en) 2001-11-22
EP1229906A2 (de) 2002-08-14
AU6946600A (en) 2001-03-26
BG106442A (bg) 2002-09-30
HUP0202429A3 (en) 2004-04-28
AU781840B2 (en) 2005-06-16
IL148416A0 (en) 2002-09-12
CO5200772A1 (es) 2002-09-27
LV12941B (en) 2003-06-20
DK1229906T3 (da) 2008-02-11
KR100864547B1 (ko) 2008-10-20
ES2295050T3 (es) 2008-04-16
HRP20020267A2 (en) 2004-04-30
WO2001015679A2 (en) 2001-03-08
EA200200282A1 (ru) 2002-10-31
BR0014161A (pt) 2002-05-21
KR100755109B1 (ko) 2007-09-04
SI20852A (sl) 2002-10-31
EE200200104A (et) 2003-04-15
CZ2002704A3 (cs) 2003-02-12
KR20020027616A (ko) 2002-04-13
AR025457A1 (es) 2002-11-27
MEP13808A (en) 2010-06-10
PT1229906E (pt) 2008-01-18
NO20020999L (no) 2002-03-14
JP2003535029A (ja) 2003-11-25
YU14002A (sh) 2006-01-16
LT2002031A (en) 2003-02-25
EP1229906B1 (de) 2007-10-10
NO20020999D0 (no) 2002-02-28
RS50283B (sr) 2009-09-08
PL198790B1 (pl) 2008-07-31
SK2992002A3 (en) 2002-07-02
LT5034B (lt) 2003-07-25
NZ517471A (en) 2004-02-27
DE60036723T2 (de) 2008-07-17
PL353930A1 (en) 2003-12-15
HUP0202429A2 (en) 2002-10-28
SI20852B (sl) 2009-06-30
BG65817B1 (bg) 2010-01-29
CA2382580C (en) 2009-05-19
RO122179B1 (ro) 2009-02-27
EE05172B1 (et) 2009-06-15
DE60036723D1 (de) 2007-11-22
SK287192B6 (sk) 2010-02-08
PE20010578A1 (es) 2001-06-04
KR20070058023A (ko) 2007-06-07
UA78184C2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE376994T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69922914D1 (de) Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux
DE60026627D1 (de) Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69823339D1 (de) Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE375160T1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60025097D1 (de) Rührvorrichtung zur kontinuierlichen Behandlung von Metallschmelzen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1229906

Country of ref document: EP

REN Ceased due to non-payment of the annual fee